Antikörper-Wirkstoff-Konjugate und deren Verwendungen
EP4741423
13. Mai 2026
Anmelder: Mablink Bioscience 🇫🇷
Details
- Veröffentlichungs-Nr.
- EP4741423
- Anmeldetag
- 10. März 2023
- Veröffentlichung
- 13. Mai 2026
- Rechtsraum
- EP
- IPC
- C07K16/32(EISAI INC et al.)(SUTRO BIOPHARMA INC et al.)(MABLINK BIOSCIENCE et al.)MULLER: "Meth Enzymol", 1983
Abstract
The present invention relates to antibody-drug conjugates, wherein the antibody specifically binds to folate receptor α, and wherein the drug is preferably chosen among a cytotoxic drug. Such antibody-drug conjugates are useful in particular in treating proliferative diseases including cancers, such as ovarian, breast and non-small cell lung cancers.
Anmelder
- Firma
- Mablink Bioscience
- Land
- 🇫🇷 Frankreich